| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 65 | 2025 | 1235 | 8.320 |
Why?
|
| Tissue and Organ Procurement | 21 | 2025 | 423 | 4.070 |
Why?
|
| Kidney Transplantation | 23 | 2026 | 939 | 4.040 |
Why?
|
| Graft Survival | 41 | 2026 | 994 | 3.400 |
Why?
|
| Tissue Donors | 24 | 2025 | 581 | 3.320 |
Why?
|
| Waiting Lists | 12 | 2025 | 237 | 1.640 |
Why?
|
| Kidney Failure, Chronic | 7 | 2025 | 445 | 1.590 |
Why?
|
| End Stage Liver Disease | 6 | 2025 | 77 | 1.470 |
Why?
|
| Graft Rejection | 17 | 2025 | 1186 | 1.380 |
Why?
|
| Liver Failure | 7 | 2023 | 72 | 1.280 |
Why?
|
| Hepatitis C | 7 | 2019 | 186 | 1.140 |
Why?
|
| Living Donors | 9 | 2024 | 375 | 1.010 |
Why?
|
| Liver Diseases | 6 | 2020 | 249 | 0.990 |
Why?
|
| Carcinoma, Hepatocellular | 6 | 2012 | 450 | 0.970 |
Why?
|
| Liver Cirrhosis | 5 | 2014 | 288 | 0.940 |
Why?
|
| Kidney | 5 | 2023 | 1123 | 0.910 |
Why?
|
| Retrospective Studies | 42 | 2026 | 10962 | 0.890 |
Why?
|
| Survival Rate | 20 | 2025 | 2041 | 0.890 |
Why?
|
| Liver Neoplasms | 6 | 2012 | 831 | 0.830 |
Why?
|
| Liver Failure, Acute | 3 | 2009 | 39 | 0.770 |
Why?
|
| Humans | 92 | 2026 | 98135 | 0.710 |
Why?
|
| Death | 6 | 2020 | 98 | 0.700 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2013 | 358 | 0.690 |
Why?
|
| Liver | 10 | 2021 | 1231 | 0.670 |
Why?
|
| Risk Factors | 21 | 2025 | 6232 | 0.660 |
Why?
|
| Transplantation, Homologous | 9 | 2026 | 1026 | 0.620 |
Why?
|
| Risk Assessment | 11 | 2020 | 2585 | 0.590 |
Why?
|
| Male | 55 | 2026 | 47109 | 0.580 |
Why?
|
| Forkhead Transcription Factors | 3 | 2013 | 183 | 0.570 |
Why?
|
| Portal Vein | 3 | 2010 | 121 | 0.570 |
Why?
|
| Postoperative Complications | 8 | 2025 | 2680 | 0.560 |
Why?
|
| Liver Circulation | 2 | 2010 | 28 | 0.560 |
Why?
|
| Follow-Up Studies | 15 | 2025 | 4026 | 0.560 |
Why?
|
| Adult | 35 | 2025 | 29564 | 0.550 |
Why?
|
| Transplant Recipients | 1 | 2020 | 182 | 0.540 |
Why?
|
| Female | 55 | 2026 | 51570 | 0.540 |
Why?
|
| Models, Statistical | 2 | 2013 | 601 | 0.520 |
Why?
|
| Patient Selection | 7 | 2025 | 725 | 0.510 |
Why?
|
| Child, Preschool | 17 | 2026 | 4006 | 0.510 |
Why?
|
| Fatty Liver | 3 | 2010 | 119 | 0.510 |
Why?
|
| Obesity | 4 | 2024 | 1061 | 0.510 |
Why?
|
| Reoperation | 6 | 2025 | 726 | 0.500 |
Why?
|
| Treatment Outcome | 24 | 2026 | 9713 | 0.490 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 811 | 0.490 |
Why?
|
| Donor Selection | 4 | 2025 | 86 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2009 | 1535 | 0.480 |
Why?
|
| Immune Tolerance | 3 | 2013 | 386 | 0.480 |
Why?
|
| Child | 20 | 2026 | 7699 | 0.470 |
Why?
|
| Transplantation Tolerance | 2 | 2008 | 145 | 0.470 |
Why?
|
| Middle Aged | 35 | 2025 | 29442 | 0.450 |
Why?
|
| Adolescent | 21 | 2026 | 10097 | 0.440 |
Why?
|
| Severity of Illness Index | 9 | 2023 | 2013 | 0.440 |
Why?
|
| Infant | 16 | 2026 | 3332 | 0.440 |
Why?
|
| Aged | 22 | 2024 | 21760 | 0.430 |
Why?
|
| Dendritic Cells | 3 | 2013 | 552 | 0.420 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 3 | 2013 | 38 | 0.410 |
Why?
|
| Prognosis | 12 | 2025 | 4116 | 0.400 |
Why?
|
| Hepatic Artery | 3 | 2012 | 84 | 0.390 |
Why?
|
| Length of Stay | 3 | 2013 | 878 | 0.390 |
Why?
|
| United States | 16 | 2026 | 8193 | 0.370 |
Why?
|
| Polymorphism, Genetic | 2 | 2006 | 831 | 0.370 |
Why?
|
| Graft vs Host Disease | 2 | 2021 | 379 | 0.360 |
Why?
|
| Hepacivirus | 6 | 2019 | 137 | 0.360 |
Why?
|
| Health Status Indicators | 1 | 2012 | 99 | 0.350 |
Why?
|
| Thinness | 2 | 2010 | 48 | 0.340 |
Why?
|
| Survival Analysis | 6 | 2014 | 1527 | 0.330 |
Why?
|
| Perfusion | 2 | 2020 | 271 | 0.330 |
Why?
|
| Antigens, CD | 3 | 2008 | 484 | 0.330 |
Why?
|
| Cause of Death | 4 | 2020 | 278 | 0.320 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2010 | 7 | 0.320 |
Why?
|
| Biopsy, Needle | 3 | 2012 | 226 | 0.310 |
Why?
|
| Critical Care | 2 | 2020 | 483 | 0.300 |
Why?
|
| Adoptive Transfer | 2 | 2006 | 174 | 0.300 |
Why?
|
| Delayed Graft Function | 3 | 2025 | 21 | 0.300 |
Why?
|
| Multivariate Analysis | 6 | 2019 | 1009 | 0.290 |
Why?
|
| Time Factors | 11 | 2025 | 5576 | 0.290 |
Why?
|
| Preoperative Care | 2 | 2009 | 418 | 0.290 |
Why?
|
| Renal Dialysis | 2 | 2024 | 357 | 0.290 |
Why?
|
| Acetaminophen | 2 | 2006 | 63 | 0.290 |
Why?
|
| Drug Monitoring | 1 | 2010 | 166 | 0.290 |
Why?
|
| Medical Errors | 1 | 2009 | 93 | 0.280 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2009 | 41 | 0.280 |
Why?
|
| Prospective Studies | 8 | 2018 | 4825 | 0.280 |
Why?
|
| Constriction, Pathologic | 2 | 2006 | 211 | 0.280 |
Why?
|
| Fatigue | 1 | 2009 | 187 | 0.280 |
Why?
|
| Body Mass Index | 4 | 2024 | 850 | 0.270 |
Why?
|
| Thrombosis | 2 | 2012 | 318 | 0.270 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2024 | 903 | 0.270 |
Why?
|
| Transplants | 2 | 2018 | 43 | 0.270 |
Why?
|
| Young Adult | 11 | 2020 | 7511 | 0.250 |
Why?
|
| Proportional Hazards Models | 8 | 2024 | 922 | 0.250 |
Why?
|
| Organ Preservation | 2 | 2025 | 139 | 0.250 |
Why?
|
| Incidence | 8 | 2019 | 1777 | 0.250 |
Why?
|
| Lymphocytic choriomeningitis virus | 1 | 2006 | 16 | 0.250 |
Why?
|
| Lymphocytic Choriomeningitis | 1 | 2006 | 11 | 0.250 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2006 | 11 | 0.250 |
Why?
|
| Hepatitis | 1 | 2006 | 32 | 0.240 |
Why?
|
| Compartment Syndromes | 1 | 2006 | 22 | 0.240 |
Why?
|
| Liver Regeneration | 1 | 2006 | 34 | 0.240 |
Why?
|
| Aprotinin | 1 | 2006 | 24 | 0.240 |
Why?
|
| Biliary Atresia | 1 | 2006 | 25 | 0.240 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2006 | 25 | 0.240 |
Why?
|
| Survival | 1 | 2006 | 22 | 0.240 |
Why?
|
| Bile Ducts | 1 | 2006 | 62 | 0.240 |
Why?
|
| Antigens, Differentiation | 1 | 2006 | 125 | 0.240 |
Why?
|
| Aged, 80 and over | 5 | 2023 | 7387 | 0.240 |
Why?
|
| Mannose-Binding Lectin | 1 | 2006 | 3 | 0.240 |
Why?
|
| Cholecystectomy | 1 | 2006 | 26 | 0.240 |
Why?
|
| Hemochromatosis | 1 | 2006 | 12 | 0.240 |
Why?
|
| Abdomen | 1 | 2006 | 120 | 0.240 |
Why?
|
| Ferric Compounds | 1 | 2006 | 41 | 0.230 |
Why?
|
| Hemostatics | 1 | 2006 | 64 | 0.230 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2006 | 105 | 0.230 |
Why?
|
| Quality of Health Care | 2 | 2006 | 391 | 0.230 |
Why?
|
| Antigen-Presenting Cells | 1 | 2006 | 146 | 0.230 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2006 | 52 | 0.230 |
Why?
|
| Ascites | 1 | 2006 | 55 | 0.230 |
Why?
|
| Viral Envelope Proteins | 1 | 2006 | 80 | 0.230 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2006 | 64 | 0.230 |
Why?
|
| Exercise Therapy | 1 | 2006 | 96 | 0.230 |
Why?
|
| Staining and Labeling | 1 | 2006 | 162 | 0.230 |
Why?
|
| Brain Death | 5 | 2020 | 94 | 0.230 |
Why?
|
| Albumins | 1 | 2006 | 127 | 0.230 |
Why?
|
| Steroids | 1 | 2006 | 168 | 0.220 |
Why?
|
| Blood Group Incompatibility | 1 | 2025 | 23 | 0.220 |
Why?
|
| Hepatitis B | 1 | 2006 | 78 | 0.220 |
Why?
|
| Serotonin | 1 | 2006 | 211 | 0.220 |
Why?
|
| Surgical Mesh | 1 | 2006 | 126 | 0.220 |
Why?
|
| Th2 Cells | 1 | 2006 | 152 | 0.220 |
Why?
|
| Immune System | 1 | 2006 | 106 | 0.220 |
Why?
|
| ABO Blood-Group System | 1 | 2025 | 58 | 0.220 |
Why?
|
| Catheter Ablation | 1 | 2009 | 381 | 0.220 |
Why?
|
| Hepatocytes | 1 | 2006 | 137 | 0.220 |
Why?
|
| Herniorrhaphy | 1 | 2006 | 95 | 0.220 |
Why?
|
| Vascular Diseases | 1 | 2006 | 120 | 0.220 |
Why?
|
| Metabolic Syndrome | 1 | 2006 | 125 | 0.210 |
Why?
|
| Infant, Newborn | 6 | 2024 | 2531 | 0.210 |
Why?
|
| HLA Antigens | 1 | 2006 | 238 | 0.210 |
Why?
|
| Bacterial Infections | 1 | 2006 | 184 | 0.210 |
Why?
|
| Intubation, Intratracheal | 1 | 2006 | 216 | 0.200 |
Why?
|
| Endothelium, Vascular | 1 | 2006 | 440 | 0.200 |
Why?
|
| Palliative Care | 1 | 2006 | 290 | 0.200 |
Why?
|
| Liver Function Tests | 4 | 2010 | 94 | 0.200 |
Why?
|
| Body Surface Area | 1 | 2023 | 38 | 0.200 |
Why?
|
| Intention to Treat Analysis | 1 | 2023 | 81 | 0.190 |
Why?
|
| Stents | 1 | 2006 | 433 | 0.190 |
Why?
|
| Immunosuppressive Agents | 3 | 2010 | 1013 | 0.190 |
Why?
|
| Organ Transplantation | 1 | 2006 | 306 | 0.190 |
Why?
|
| Immunity, Innate | 1 | 2006 | 481 | 0.190 |
Why?
|
| Mice, Inbred C3H | 3 | 2008 | 370 | 0.190 |
Why?
|
| Critical Illness | 1 | 2006 | 436 | 0.180 |
Why?
|
| Policy | 1 | 2022 | 41 | 0.180 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 2668 | 0.180 |
Why?
|
| Cohort Studies | 7 | 2020 | 3213 | 0.180 |
Why?
|
| Residence Characteristics | 1 | 2024 | 224 | 0.180 |
Why?
|
| Allografts | 4 | 2026 | 218 | 0.180 |
Why?
|
| Geography | 1 | 2022 | 249 | 0.170 |
Why?
|
| Proteome | 2 | 2014 | 163 | 0.170 |
Why?
|
| Socioeconomic Factors | 1 | 2024 | 663 | 0.170 |
Why?
|
| Insulin | 1 | 2006 | 1227 | 0.160 |
Why?
|
| Hypertension | 1 | 2006 | 778 | 0.160 |
Why?
|
| Health Policy | 1 | 2022 | 216 | 0.160 |
Why?
|
| Acute Kidney Injury | 1 | 2025 | 372 | 0.160 |
Why?
|
| Washington | 3 | 2024 | 51 | 0.150 |
Why?
|
| Age Factors | 6 | 2024 | 1967 | 0.150 |
Why?
|
| Social Class | 1 | 2020 | 156 | 0.150 |
Why?
|
| Cold Ischemia | 3 | 2010 | 22 | 0.150 |
Why?
|
| Laparoscopy | 1 | 2006 | 792 | 0.150 |
Why?
|
| Mice | 7 | 2013 | 12697 | 0.150 |
Why?
|
| Insurance, Health | 1 | 2020 | 186 | 0.140 |
Why?
|
| Databases, Factual | 4 | 2019 | 1090 | 0.140 |
Why?
|
| Body Weight | 3 | 2010 | 455 | 0.140 |
Why?
|
| Terminal Care | 1 | 2020 | 148 | 0.140 |
Why?
|
| Hepatitis C Antibodies | 1 | 2018 | 8 | 0.140 |
Why?
|
| Tacrolimus | 2 | 2010 | 376 | 0.140 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 1784 | 0.130 |
Why?
|
| Blood Flow Velocity | 2 | 2010 | 179 | 0.130 |
Why?
|
| Quality Control | 1 | 2018 | 130 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2020 | 234 | 0.130 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2008 | 2555 | 0.130 |
Why?
|
| Antilymphocyte Serum | 1 | 1997 | 68 | 0.130 |
Why?
|
| Muromonab-CD3 | 1 | 1997 | 70 | 0.130 |
Why?
|
| Histocompatibility Testing | 2 | 2008 | 145 | 0.130 |
Why?
|
| Animals | 9 | 2013 | 28902 | 0.130 |
Why?
|
| Logistic Models | 3 | 2010 | 1275 | 0.130 |
Why?
|
| Medicaid | 1 | 2020 | 276 | 0.130 |
Why?
|
| Erythrocyte Transfusion | 1 | 2018 | 82 | 0.130 |
Why?
|
| CTLA-4 Antigen | 2 | 2008 | 146 | 0.130 |
Why?
|
| Probability | 2 | 2009 | 356 | 0.120 |
Why?
|
| Intestines | 2 | 2010 | 441 | 0.120 |
Why?
|
| Cell Transplantation | 2 | 2006 | 46 | 0.120 |
Why?
|
| Needs Assessment | 2 | 2009 | 174 | 0.120 |
Why?
|
| Mice, Inbred Strains | 2 | 2006 | 281 | 0.120 |
Why?
|
| Glucose Tolerance Test | 2 | 2006 | 239 | 0.120 |
Why?
|
| Proteomics | 2 | 2014 | 279 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 539 | 0.110 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1996 | 0.100 |
Why?
|
| Cyclosporine | 2 | 2008 | 241 | 0.100 |
Why?
|
| CD4 Antigens | 1 | 2013 | 81 | 0.100 |
Why?
|
| Methylprednisolone | 2 | 2006 | 65 | 0.090 |
Why?
|
| Decision Making | 1 | 2018 | 686 | 0.090 |
Why?
|
| Registries | 3 | 2010 | 1122 | 0.090 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 53 | 0.090 |
Why?
|
| Cytomegalovirus Infections | 2 | 2006 | 116 | 0.090 |
Why?
|
| B7-H1 Antigen | 1 | 2013 | 332 | 0.080 |
Why?
|
| RNA, Viral | 2 | 2010 | 288 | 0.080 |
Why?
|
| Medical Futility | 1 | 2010 | 35 | 0.080 |
Why?
|
| Intraoperative Period | 1 | 2010 | 93 | 0.080 |
Why?
|
| Gastroschisis | 1 | 2010 | 8 | 0.080 |
Why?
|
| Factor Analysis, Statistical | 1 | 2010 | 118 | 0.080 |
Why?
|
| Reperfusion | 1 | 2010 | 33 | 0.080 |
Why?
|
| Intestinal Volvulus | 1 | 2010 | 10 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2008 | 3598 | 0.080 |
Why?
|
| Transplantation | 1 | 2010 | 39 | 0.080 |
Why?
|
| Short Bowel Syndrome | 1 | 2010 | 38 | 0.080 |
Why?
|
| Antiviral Agents | 2 | 2006 | 369 | 0.080 |
Why?
|
| Heart Transplantation | 2 | 2006 | 873 | 0.080 |
Why?
|
| Hepatitis C, Chronic | 1 | 2010 | 95 | 0.070 |
Why?
|
| Bilirubin | 1 | 2009 | 135 | 0.070 |
Why?
|
| Intestinal Diseases | 1 | 2010 | 84 | 0.070 |
Why?
|
| DNA, Viral | 1 | 2010 | 238 | 0.070 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2010 | 86 | 0.070 |
Why?
|
| Kidney Function Tests | 2 | 2025 | 122 | 0.070 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2008 | 45 | 0.070 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2008 | 77 | 0.070 |
Why?
|
| Calcineurin Inhibitors | 1 | 2008 | 55 | 0.070 |
Why?
|
| Workload | 1 | 2009 | 130 | 0.070 |
Why?
|
| Bile Duct Diseases | 1 | 2008 | 23 | 0.070 |
Why?
|
| Intraoperative Complications | 1 | 2009 | 194 | 0.070 |
Why?
|
| Interleukin-4 | 1 | 2008 | 136 | 0.070 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2010 | 220 | 0.070 |
Why?
|
| Risk | 3 | 2019 | 660 | 0.070 |
Why?
|
| ROC Curve | 1 | 2010 | 795 | 0.070 |
Why?
|
| Cost-Benefit Analysis | 1 | 2010 | 523 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2008 | 218 | 0.060 |
Why?
|
| Quality of Life | 2 | 2006 | 1895 | 0.060 |
Why?
|
| CD4-CD8 Ratio | 1 | 2006 | 18 | 0.060 |
Why?
|
| Mice, Obese | 1 | 2006 | 50 | 0.060 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2006 | 65 | 0.060 |
Why?
|
| Warm Ischemia | 1 | 2006 | 34 | 0.060 |
Why?
|
| Hepatic Encephalopathy | 1 | 2006 | 35 | 0.060 |
Why?
|
| Bezafibrate | 1 | 2006 | 5 | 0.060 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 88 | 0.060 |
Why?
|
| Polypropylenes | 1 | 2006 | 23 | 0.060 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2006 | 19 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1815 | 0.060 |
Why?
|
| Microcirculation | 1 | 2006 | 101 | 0.060 |
Why?
|
| Leptin | 1 | 2006 | 101 | 0.060 |
Why?
|
| Homozygote | 1 | 2006 | 212 | 0.060 |
Why?
|
| Restriction Mapping | 1 | 2006 | 119 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2009 | 508 | 0.060 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 40 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 200 | 0.060 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 194 | 0.060 |
Why?
|
| Chimera | 1 | 2006 | 52 | 0.060 |
Why?
|
| Cytomegalovirus | 1 | 2006 | 74 | 0.060 |
Why?
|
| Metabolic Diseases | 1 | 2006 | 60 | 0.060 |
Why?
|
| Glucose Intolerance | 1 | 2006 | 101 | 0.060 |
Why?
|
| Cricetinae | 1 | 2006 | 533 | 0.060 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2006 | 44 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2008 | 356 | 0.060 |
Why?
|
| Interleukin-10 | 1 | 2006 | 167 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2008 | 743 | 0.060 |
Why?
|
| Herpesvirus 4, Human | 1 | 2006 | 124 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2006 | 220 | 0.060 |
Why?
|
| Spleen | 1 | 2006 | 375 | 0.060 |
Why?
|
| Psychology | 1 | 2005 | 28 | 0.060 |
Why?
|
| T-Lymphocytes | 2 | 2006 | 1327 | 0.060 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 101 | 0.060 |
Why?
|
| Long-Term Care | 1 | 2006 | 66 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 148 | 0.060 |
Why?
|
| Mice, SCID | 1 | 2006 | 278 | 0.060 |
Why?
|
| Linear Models | 1 | 2006 | 424 | 0.060 |
Why?
|
| Heterozygote | 1 | 2006 | 390 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 271 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2006 | 412 | 0.060 |
Why?
|
| Reperfusion Injury | 1 | 2006 | 148 | 0.060 |
Why?
|
| Diarrhea | 1 | 2006 | 180 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2006 | 100 | 0.050 |
Why?
|
| Monocytes | 1 | 2006 | 219 | 0.050 |
Why?
|
| Catheterization | 1 | 2006 | 219 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2006 | 297 | 0.050 |
Why?
|
| Suicide, Attempted | 1 | 2006 | 145 | 0.050 |
Why?
|
| Transplantation, Heterologous | 1 | 2006 | 375 | 0.050 |
Why?
|
| Drug Overdose | 1 | 2006 | 103 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2006 | 395 | 0.050 |
Why?
|
| Haplotypes | 1 | 2006 | 656 | 0.050 |
Why?
|
| Autoimmune Diseases | 1 | 2006 | 259 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2006 | 839 | 0.050 |
Why?
|
| Species Specificity | 1 | 2006 | 690 | 0.050 |
Why?
|
| Perioperative Care | 1 | 2006 | 198 | 0.050 |
Why?
|
| Gene Expression | 1 | 2008 | 1320 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2005 | 236 | 0.050 |
Why?
|
| Radiography | 1 | 2006 | 763 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2006 | 358 | 0.050 |
Why?
|
| Biomarkers | 1 | 2010 | 2022 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2025 | 299 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2006 | 391 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2010 | 1445 | 0.050 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2006 | 502 | 0.050 |
Why?
|
| Alleles | 1 | 2006 | 1159 | 0.050 |
Why?
|
| Chromatography, Liquid | 2 | 2014 | 102 | 0.050 |
Why?
|
| Mass Spectrometry | 2 | 2014 | 191 | 0.050 |
Why?
|
| Cytokines | 1 | 2006 | 889 | 0.040 |
Why?
|
| Apoptosis | 1 | 2008 | 1752 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2006 | 1012 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2006 | 520 | 0.040 |
Why?
|
| Portacaval Shunt, Surgical | 1 | 2001 | 7 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2006 | 449 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 508 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2021 | 340 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2006 | 2855 | 0.040 |
Why?
|
| Biopsy | 2 | 2010 | 1224 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 1416 | 0.040 |
Why?
|
| Recurrence | 3 | 2012 | 1254 | 0.040 |
Why?
|
| Advance Care Planning | 1 | 2020 | 45 | 0.040 |
Why?
|
| Rats | 1 | 2006 | 4072 | 0.040 |
Why?
|
| Shock | 1 | 2020 | 56 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2006 | 1646 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2001 | 264 | 0.040 |
Why?
|
| Cadaver | 1 | 2019 | 200 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 2572 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2006 | 2558 | 0.030 |
Why?
|
| Erythrocyte Count | 1 | 2018 | 21 | 0.030 |
Why?
|
| Plasma | 1 | 2018 | 49 | 0.030 |
Why?
|
| Machine Learning | 1 | 2021 | 408 | 0.030 |
Why?
|
| Acyclovir | 1 | 1997 | 35 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 3618 | 0.030 |
Why?
|
| Azathioprine | 1 | 1997 | 127 | 0.030 |
Why?
|
| Disease Progression | 2 | 2012 | 1610 | 0.030 |
Why?
|
| Acute Disease | 1 | 1997 | 860 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 1997 | 370 | 0.030 |
Why?
|
| Mutation | 1 | 2006 | 4392 | 0.030 |
Why?
|
| Ions | 1 | 2014 | 75 | 0.030 |
Why?
|
| Thrombophilia | 1 | 2012 | 22 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2012 | 75 | 0.020 |
Why?
|
| Models, Animal | 1 | 2013 | 282 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 128 | 0.020 |
Why?
|
| Reference Values | 1 | 2012 | 612 | 0.020 |
Why?
|
| Serum | 1 | 2010 | 26 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2012 | 299 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 303 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 360 | 0.020 |
Why?
|
| Genotype | 2 | 2008 | 1888 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2012 | 339 | 0.020 |
Why?
|
| Health Care Rationing | 1 | 2010 | 85 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2010 | 213 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C8 | 1 | 2008 | 3 | 0.020 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2008 | 11 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2012 | 489 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2008 | 63 | 0.020 |
Why?
|
| Overweight | 1 | 2009 | 123 | 0.020 |
Why?
|
| Demography | 1 | 2008 | 193 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1948 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 1138 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2010 | 560 | 0.010 |
Why?
|
| Kinetics | 1 | 2008 | 1476 | 0.010 |
Why?
|
| Portal System | 1 | 2001 | 12 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 1997 | 1193 | 0.010 |
Why?
|